查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735624

全球人類狂犬病疫苗市場規模（按細胞株類型、應用、分銷管道、區域覆蓋範圍和預測）

Global Human Rabies Vaccines Market Size By Cell Line Type, By Application, By Distribution Channel, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

人類狂犬病疫苗市場規模及預測

2024 年人類狂犬病疫苗市場規模為 12.3 億美元，預計到 2032 年將達到 19.1 億美元，2026 年至 2032 年的複合年成長率為 5.7%。

  • 人類用狂犬病疫苗是保護人類免受狂犬病毒感染的生技藥品，通常由去活化的狂犬病毒體或病毒產生的重組蛋白組成。
  • 這些疫苗刺激免疫系統形成針對狂犬病毒的抗體，以防止將來接觸狂犬病毒。
  • 人類狂犬病疫苗通常在接觸病毒後注射在手臂上，或作為接觸狂犬病動物高風險人群的預防措施，例如獸醫、動物控制工作者和前往狂犬病常見地區的旅行者。
  • 此外，人類狂犬病疫苗在預防狂犬病毒感染的致命後果方面發揮著重要作用。

狂犬病疫苗的全球市場動態

影響人類狂犬病疫苗市場的關鍵市場動態是：

關鍵市場促進因素

  • 全球狂犬病發生率上升：全球狂犬病發生率激增，主要原因是流浪犬攻擊，這刺激了對人類狂犬病疫苗的需求。預防狂犬病感染需要全面的疫苗接種計劃，這推動了市場擴張。
  • 政府措施和疫苗接種計畫：為了消除狂犬病，世界各國政府進行了宣傳和疫苗宣傳活動。這些計劃通常包括免費或津貼疫苗接種，在促進人類狂犬病疫苗的使用和分發方面發揮重要作用。
  • 疫苗研發的進展：細胞培養疫苗和重組疫苗等新型高效狂犬病疫苗的研發正在顯著推動市場發展。這些疫苗的安全性和有效性均有所提升，並有望促進其更廣泛地普及和使用。
  • 旅行和前往狂犬病流行地區的次數增加：國際旅行，尤其是在狂犬病流行地區的旅行，會增加感染狂犬病的風險。這導致旅行者暴露前預防用藥的增加，以及對人類狂犬病疫苗的需求增加。

主要挑戰

  • 高成本和高可及性：狂犬病疫苗價格昂貴，在偏遠和低度開發地區又十分稀缺，這構成了重大障礙。這些限制因素限制了人們獲得重要疫苗接種服務的機會，尤其是在狂犬病流行且最需要疫苗接種的地區。
  • 低溫運輸物流與儲存：狂犬病疫苗需要低溫運輸系統進行儲存和運輸，而該系統的維護難度較大，尤其是在資源匱乏的地區。低溫運輸中斷會影響疫苗的有效性，為大規模疫苗宣傳活動帶來物流障礙，並限制市場擴張。
  • 缺乏認知和教育：在許多狂犬病流行地區，人們對狂犬病和疫苗接種重要性的認知度較低。這種認知不足導致現有疫苗使用不足，阻礙了控制和消除狂犬病的努力。

主要趨勢：

  • 細胞培養疫苗的興起：細胞培養疫苗作為傳統雞蛋疫苗的替代品，正日益受到歡迎。人們認為，細胞培養疫苗更安全、更有效、副作用更少，在暴露前和暴露後預防中越來越受歡迎。
  • 免疫接種與數位健康記錄整合：數位健康平台擴大被用於追蹤免疫接種訊息，包括狂犬病疫苗接種情況。這種整合改善了對疫苗接種覆蓋率和接種計劃的監測，從而提高了免疫接種計畫的效率和患者的依從性。
  • 官民合作關係(PPP)：各國政府和醫療機構已與私人疫苗生產商達成協議，以提高狂犬病疫苗的可近性和可負擔性。這些 PPP 旨在將疫苗接種計畫擴大到服務匱乏的人群，並加強全球控制和消除狂犬病的努力。
  • 重點在於單劑量疫苗研究：研發工作正轉向開發有效的單劑量狂犬病疫苗。單劑量疫苗可以簡化疫苗接種方法，提高遵從率，並縮短暴露後的反應時間。

目錄

第1章 人用狂犬病疫苗全球市場介紹

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第 2 章 已驗證的市場研究調查方法

  • 資料探勘
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 業界專家的重要見解
  • 資料來源

第3章執行摘要

  • 市場概覽
  • 生態測繪
  • 絕對的商機
  • 市場吸引力
  • 全球人類狂犬病疫苗市場區域分析
  • 全球人類狂犬病疫苗市場（依細胞株類型）
  • 全球人類狂犬病疫苗市場（按應用）
  • 全球人類狂犬病疫苗市場（按分銷管道）
  • 未來市場機會
  • 世界市場結構
  • 產品生命線

4. 人類狂犬病疫苗的全球市場展望

  • 世界各地人類狂犬病疫苗的演變
  • 驅動程式
    • 促進要素1
    • 促進要素2
  • 限制因素
    • 約束因素 1
    • 約束因素 2
  • 機會
    • 機會1
    • 機會2
  • 波特五力模型
  • 價值鏈分析
  • 定價分析
  • 宏觀經濟分析

5. 全球人類狂犬病疫苗市場（依細胞株類型）

  • 概述
  • 雞胚胎細胞
  • Vero細胞
  • BHK細胞
  • 其他

6. 全球人類狂犬病疫苗市場（依應用）

  • 概述
  • 暴露後預防
  • 暴露前預防

7. 全球狂犬病疫苗市場（依分銷管道）

  • 概述
  • 醫院藥房
  • 零售藥局
  • 線上通路

8. 全球人類狂犬病疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 陶氏化學巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

9. 全球人類狂犬病疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要進展
  • 公司地理分佈
  • 公司在各行業的足跡
  • ACE矩陣

第10章 公司簡介

  • Sanofi Pasteur
  • Merck & Co.
  • GSK
  • Bavarian Nordic A/S
  • China National Biotec Group Co.
  • Wuhan Institute of Biological Products Co.
  • The Serum Institute of India Ltd.
  • Bharat Biotech International Limited
  • Valneva SE
  • Virbac SA

第11章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第12章 已驗證的市場情報

  • 關於已驗證的市場情報
  • 動態資料視覺化
簡介目錄
Product Code: 35766

Human Rabies Vaccines Market Size And Forecast

Human Rabies Vaccines Market size was valued at USD 1.23 Billion in 2024 and is projected to reach USD 1.91 Billion by 2032, growing at a CAGR of 5.7% from 2026 to 2032.

  • Human rabies vaccines are biologics that prevent humans from becoming infected with the rabies virus. They are usually composed of inactivated rabies virus particles or recombinant proteins produced from the virus.
  • These vaccinations stimulate the immune system to develop antibodies against the rabies virus, protecting against future exposure.
  • Human rabies vaccines are given in a series of injections, usually in the arm, after being exposed to the virus or as a preventive measure for people who are at high risk of encountering rabid animals, such as veterinarians, animal control workers, and travelers to areas where rabies is common.
  • Moreover, human rabies vaccines play an important role in preventing the potentially lethal consequences of rabies virus infection.

Global Human Rabies Vaccines Market Dynamics

The key market dynamics that are shaping the Human Rabies Vaccines Market include:

Key Market Drivers:

  • Growing Incidence of Rabies Worldwide: The global surge in rabies incidence, mainly in Asia and Africa as a result of stray dog attacks, has fueled demand for human rabies vaccines. Efforts to prevent rabies infections demand comprehensive vaccination programs, driving market expansion.
  • Government Initiatives and Vaccination Programs: To eradicate rabies, governments around the world have started awareness and immunization campaigns. These programs frequently feature free or subsidized immunization, which is critical in promoting the use and distribution of human rabies vaccines.
  • Advancements in Vaccine Development: The development of new and more efficient rabies vaccinations, such as cell culture and recombinant vaccines, has significantly boosted the market. These vaccines have improved safety and efficacy characteristics, encouraging greater adoption and use.
  • Increased Travel and Exposure to Rabies-Prone Areas: There's a greater chance of contracting rabies when traveling internationally, particularly in regions where the disease is more common. This has resulted in an increase in pre-exposure prophylaxis among travelers, fueling the demand for human rabies vaccines.

Key Challenges:

  • High Cost and Accessibility Issues: Rabies vaccines are expensive and scarce in remote or undeveloped areas, posing substantial obstacles. These constraints limit access to important vaccination services, particularly in locations where rabies is endemic and vaccinations are most needed.
  • Cold Chain Logistics and Storage: Rabies vaccines necessitate a cold chain system for storage and transportation, which is challenging to maintain, particularly in low-resource areas. Breaks in the cold chain jeopardize vaccine efficacy, creating a logistical obstacle for extensive vaccination campaigns and limiting market expansion.
  • Lack of Awareness and Education: Many rabies-endemic locations have a low level of awareness about the disease and the significance of vaccination. This lack of understanding resulted in the underuse of existing vaccines, impeding attempts to control and eradicate rabies.

Key Trends:

  • Emergence of Cell Culture Vaccines: Cell culture vaccines are becoming increasingly popular as an alternative to traditional egg-based immunizations. Cell culture vaccines are seen as safer, more effective, and have fewer side effects, making them increasingly popular in both pre-exposure prophylactic and post-exposure therapies.
  • Integration of Immunization with Digital Health Records: Digital health platforms are increasingly being utilized to track vaccination information, including rabies shots. This integration allows for improved monitoring of vaccine coverage and schedules, increasing the efficiency of immunization programs and patient compliance.
  • Public-Private Partnerships (PPPs) for Vaccine Accessibility: Governments and healthcare groups are forging agreements with private-sector vaccine makers to improve rabies vaccine accessibility and affordability. These PPPs seek to expand immunization programs to underserved groups, thereby strengthening worldwide efforts to control and eliminate rabies.
  • Focus on Research for Single-Dose Vaccines: Research and development efforts are increasingly centered on developing effective single-dose rabies vaccinations. A single-dose vaccine would simplify immunization methods, enhance compliance rates, and potentially accelerate response times in post-exposure settings, all of which would have a substantial impact on public health outcomes.

Global Human Rabies Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Human Rabies Vaccines Market:

Asia Pacific:

  • According to Verified Market Research, Asia Pacific is estimated to dominate the Human Rabies Vaccines Market during the forecast period. Asia Pacific has some of the highest rates of rabies globally, partly due to massive stray dog populations in countries like India and China. This high frequency creates a significant need for human rabies vaccines, making the region an important market for these products.
  • Governments in the Asia Pacific region have initiated aggressive rabies control and elimination programs, including mass vaccination of animals and humans. These measures considerably contribute to increased demand for rabies vaccines, which strengthens the market in this region.
  • In the Asia Pacific region, public awareness of rabies and its prevention is increasing, due in part to educational efforts launched by health organizations and governments. This increased awareness has resulted in greater vaccination rates, which is fueling the market's growth.
  • Furthermore, the Asia Pacific region's rapid development and extension of healthcare infrastructure, including increasing healthcare spending and the formation of new healthcare institutions, has expanded public access to vaccines. This infrastructure expansion enables more widespread distribution and administration of rabies vaccines.

Latin America:

  • The expansion of urban areas in Latin America has resulted in more pet ownership and interaction with wildlife, increasing the danger of rabies spread. This tendency increases demand for pre-exposure prophylactic and post-exposure therapies, hence expanding the Human Rabies Vaccines Market.
  • Many Latin American countries have carried out large rabies vaccination efforts for both animals and humans, particularly in rural and urban peripheral areas. These government-led programs are critical drivers of increased demand and distribution of rabies vaccines throughout the region.
  • Furthermore, in Latin American countries, the growth of healthcare services and improved access to medical care have permitted increased vaccination coverage. This includes rural healthcare programs and the creation of clinics in underserved areas, which will drive the demand for rabies vaccines by making them more accessible to a larger population.

Middle East & Africa:

  • The Middle East and Africa region has a high incidence of rabies cases, mostly due to stray dog populations and animals. This prevalence needs the continued and growing use of rabies vaccines, which drives market growth in both preventive and post-exposure therapies.
  • Several nations in the region have initiated attempts to eradicate rabies, such as mass vaccination of animals and public health campaigns urging immunization. These initiatives by governmental and non-governmental organizations have considerably increased the demand for human rabies vaccines.
  • Furthermore, International health organizations and philanthropists are increasingly sponsoring rabies prevention and control projects throughout the Middle East and Africa. This external financing and technical aid make vaccine procurement and distribution easier, increasing the region's ability to effectively combat rabies.

Global Human Rabies Vaccines Market: Segmentation Analysis

The Global Human Rabies Vaccines Market is segmented based on Cell Line Type, Application, Distribution Channel, And Geography.

Human Rabies Vaccines Market, By Cell Line Type

  • Chick Embryo Cell
  • Vero Cell
  • BHK Cell
  • Others

Based on Cell Line Type, the market is segmented into Chick Embryo Cells, Vero Cells, BHK Cells, and Others. The chick embryo cell segment is estimated to dominate the Human Rabies Vaccines Market due to the long-standing usage of chick embryo cells in the manufacture of rabies vaccines, which are known for their efficacy and safety. Vaccines made from chick embryo cell culture are widely used in immunization programs around the world, thanks in part to their long history of usage and thorough safety data. Furthermore, the synthesis procedure employing chick embryo cells is cost-effective and well-optimized, making these vaccines accessible and economical for large-scale immunization programs, particularly in underdeveloped countries where rabies is prevalent.

Human Rabies Vaccines Market, By Application

  • Post-exposure Prophylaxis
  • Pre-exposure Prophylaxis

Based on Application, the market is segmented into Post-exposure Prophylaxis and Pre-exposure Prophylaxis. The post-exposure prophylaxis segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the critical requirement for rabies vaccination following potential exposure to the rabies virus, which can be acquired by bites or scratches from infected animals. In many areas, particularly those where rabies is endemic, the danger of exposure is considerable, demanding early treatment to avoid the development of the disease, which is almost invariably fatal once symptoms appear. Post-exposure prophylaxis (PEP) entails delivering the rabies vaccination soon after exposure to prevent the virus from developing into an active disease.

Human Rabies Vaccines Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channel

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Channel. The hospital pharmacies segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the essential role hospital pharmacists play in administering post-exposure prophylaxis (PEP), which needs prompt medical attention. Hospitals are the major treatment locations for rabies exposures because they can give both the vaccination and the required immunoglobulins, as well as skilled medical monitoring. Furthermore, in many locations, rabies vaccines are provided as part of government-led health campaigns, with hospitals serving as the primary distribution and administration sites.

Key Players

  • The "Human Rabies Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi Pasteur, Merck & Co., GSK, Bavarian Nordic A/S, China National Biotec Group Co., Wuhan Institute of Biological Products Co., The Serum Institute of India Ltd., Bharat Biotech International Limited, Valneva SE, Virbac SA, Crucell NV, Institute of Viral Diseases and CanSino Biologics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Human Rabies Vaccines Market Recent Developments
  • In December 2022, Everest Medicines announced the launch of a novel mRNA Rabies Vaccine development and the completion of a preclinical proof-of-concept study. This is a collaboration with Providence Therapeutics that focuses on a new rabies vaccine candidate.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN RABIES VACCINES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Human Rabies Vaccines Market Geographical Analysis (CAGR %)
  • 3.6 Global Human Rabies Vaccines Market, By Cell Line Type (USD Million)
  • 3.7 Global Human Rabies Vaccines Market, By Application (USD Million)
  • 3.8 Global Human Rabies Vaccines Market, By Distribution Channel (USD Million)
  • 3.9 Future Market Opportunities
  • 3.10 Global Market Split
  • 3.11 Product Life Line

4 GLOBAL HUMAN RABIES VACCINES MARKET OUTLOOK

  • 4.1 Global Human Rabies Vaccines Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL HUMAN RABIES VACCINES MARKET, BY CELL LINE TYPE

  • 5.1 Overview
  • 5.2 Chick Embryo Cell
  • 5.3 Vero Cell
  • 5.4 BHK Cell
  • 5.5 Others

6 GLOBAL HUMAN RABIES VACCINES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Post-exposure Prophylaxis
  • 6.3 Pre-exposure Prophylaxis

7 GLOBAL HUMAN RABIES VACCINES MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Channel

8 GLOBAL HUMAN RABIES VACCINES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Dow Chemical Company Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America
  • 8.6 Middle-East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of Middle-East and Africa

9 GLOBAL HUMAN RABIES VACCINES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Developments
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 Sanofi Pasteur
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Product Benchmarking
    • 10.1.4 Key Developments
  • 10.2 Merck & Co.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GSK
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Bavarian Nordic A/S
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 China National Biotec Group Co.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Wuhan Institute of Biological Products Co.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 The Serum Institute of India Ltd.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Bharat Biotech International Limited
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Valneva SE
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Virbac SA
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12. VERIFIED MARKET INTELLIGENCE

  • 12.1 About Verified Market Intelligence
  • 12.2 Dynamic Data Visualization